Podcast

Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC

Author(s):

Urology Times staff

In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.

Related Videos
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
Human Body Organs (Urinary Bladder) | Image Credit: @ magicmine - stock.adobe.com
April 21st 2025

Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan

Hannah Clarke
Treatment with nadofaragene led to a complete response rate of 75% at 3 months.
Introducing Pearls & Perspectives, with Amy Pearlman, MD!
April 21st 2025

Introducing Pearls & Perspectives, with Amy Pearlman, MD!

Amy M. Pearlman, MD
Pearls & Perspectives, hosted by Amy Pearlman, MD, is the latest multimedia program from Urology Times.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
April 17th 2025

NMIBC Clinical Forums highlight novel therapies and treatment strategies

Urology Times staff
Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA approval sought for Anktiva in papillary NMIBC
April 15th 2025

FDA approval sought for Anktiva in papillary NMIBC

Hannah Clarke
The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.
What urologists can expect in Q2 of 2025
April 7th 2025

What urologists can expect in Q2 of 2025

Hannah Clarke Benjamin P. Saylor
A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
© 2025 MJH Life Sciences

All rights reserved.